MetaVia Inc. (MTVA)
NASDAQ: MTVA · Real-Time Price · USD
0.7099
-0.0081 (-1.13%)
At close: Jul 14, 2025, 4:00 PM
0.6900
-0.0199 (-2.80%)
After-hours: Jul 14, 2025, 4:28 PM EDT
MetaVia Employees
MetaVia had 9 employees as of December 31, 2024. The number of employees increased by 1 or 12.50% compared to the previous year.
Employees
9
Change (1Y)
1
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$2,727,667
Market Cap
13.60M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MTVA News
- 5 days ago - MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose - PRNewsWire
- 23 days ago - MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session - PRNewsWire
- 4 weeks ago - MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th - GlobeNewsWire
- 5 weeks ago - MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions - PRNewsWire
- 2 months ago - MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules - PRNewsWire
- 2 months ago - MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 - PRNewsWire
- 2 months ago - MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 - PRNewsWire